SeaStar Medical Holding Corporation (ICU), a commercial-stage healthcare company focused on therapies for critically ill patients facing organ failure, is scheduled to present at the NobleCon21 Investor Conference in Boca Raton, Florida, on December 3, 2025.
The company will showcase its therapeutic platform and growth strategy at NobleCon21, where management is expected to discuss the company's commercial progress, clinical milestones, and financial positioning.
SeaStar's first commercial product based on its patented Selective Cytopheretic Device (SCD) technology is QUELIMMUNE (SCD-PED) therapy, the only FDA-approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients.
Real-world registry data demonstrated survival rates of 76% at 60 days and 71% at 90 days in treated patients.
The company is also exploring its Selective Cytopheretic Device therapy in a pivotal phase 3 trial in adults with acute kidney injury requiring continuous renal replacement therapy, dubbed NEUTRALIZE-AKI. The trial is now expected to enrol 339 patients following a positive interim analysis showing a signal toward efficacy. To date, 146 patients have been enrolled, and completion is expected by the end of 2026.
A feasibility study evaluating the Selective Cytopheretic Device therapy for the reduction of inflammation in adult patients with acute heart failure with worsening renal function due to cardiorenal syndrome or severe right ventricular failure awaiting a LVAD implantation, dubbed NEUTRALIZE-CRS, is also underway.
The company recently reported financial results for the third quarter ended September 30, 2025.
Net revenue was primarily generated from QUELIMMUNE pediatric therapy sales. The product generated approximately $0.2 million in revenue during Q3 2025, compared with $0.1 million in Q3 2024, and has shown strong early commercial traction, with Q4, 2025 orders already exceeding those of Q3, 2025.
Net loss narrowed to $3.5 million, or $0.13 per share, versus $4.5 million, or $1.10 per share, in the prior-year quarter.
Research and development expenses declined to $1.9 million from $2.3 million in Q3 2024, driven by lower consulting and personnel costs, while general and administrative expenses decreased to $1.9 million from $2.2 million.
Cash as of September 30, 2025, stood at $13.8 million, bolstered by $12.4 million raised through equity offerings and warrant exercises during the quarter.
ICU has traded in a range of $0.30 to $3.07 over the past year. The stock closed Friday's trading at $0.30, down 1.61%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.